Movement Alert|Boston Scientific Rises 3.43% in Regular Trading, Healthcare Equipment Sector Broadly Rallies

Market Focus07-16

On July 16, Boston Scientific rose 3.43% in regular trading, trading at $45.33 USD/share, with turnover of $89.52 million. The stock advanced alongside a broad rally across the Health Care Equipment sector, with Abbott Laboratories surging over 11% and leading gains industrywide.

Within the Health Care Equipment sector, the overall sector showed strong momentum. Among individual stocks, Abbott Laboratories up 11.65%, Stryker up 5.15%, Medtronic up 4.14%, Intuitive Surgical up 3.42%, IDEXX Laboratories up 3.33%. Boston Scientific's advance came despite Truist on the same day trimming its price target slightly to $62 from $64 while maintaining its Buy rating. The FactSet consensus mean target now stands at $71.36, still well above the current trading level.

The rebound follows a period of significant analyst target price reductions since late April, with firms including Jefferies, RBC, Needham, Piper Sandler, and BofA Securities cutting targets by 25%-35% on average amid headwinds from the Watchman device and a company-issued guidance reset. Management has maintained full-year organic revenue growth guidance of 6.5% to 8%, with Q2 expected as the trough quarter. The next earnings report is scheduled for July 29.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment